Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bardet-Biedl syndrome 2 protein (BBS2) is a core subunit of the BBSome, an octameric protein complex essential for primary cilia function and homeostasis[1][2][4][5][6]. The BBSome acts as a cargo adaptor, sorting and trafficking specific membrane proteins—such as G-protein coupled receptors (GPCRs)—to and from the ciliary membrane via the intraflagellar transport system[2][5][6]. BBS2 forms a dimer with BBS7 via a coiled-coil interaction and interacts with BBS9 through its α-helical domain, forming a critical assembly intermediate of the BBSome complex[1][4]. Mutations in BBS2 disrupt BBSome assembly, resulting in defective ciliary transport and the clinical manifestations of Bardet-Biedl syndrome, a genetically heterogeneous ciliopathy presenting with retinal dystrophy, obesity, polydactyly, renal abnormalities, and hypogenitalism, among other features[1][3][5]. Although fundamental to ciliary protein transport, there are no known pharmacological agents directly targeting BBS2 as a therapeutic approach. Pathogenic variants in BBS2 serve as diagnostic markers for Bardet-Biedl syndrome in clinical genetics[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bardet-Biedl syndrome 2 protein (BBS2).